{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (H23N-001) IND: 112952', 'Protocol: HZNP-TEP-302', 'Date: 31 January 2019', 'Version 3.0, incorporating Protocol Version 2.1 and Amandment 2', 'SPONSOR SIGNATURE PAGE', 'Protocol Number:', 'HZNP-TEP-302', 'Version:', '3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Protocol Title:', 'Multicenter, Safety.and Efficacy, Open-Label Extension Study Evaluating', 'Teprotumumab (HZN-001) Treatment in Subjects with Thyroid Eye', 'Disease (OPTIC-X)', 'Version Date:', '31 January 2019', 'Approved by:', 'OOFEB2019', 'Date', 'Horizon Pharma USA, Inc.', '2-6-19', 'Date', '2.2.19', 'Date', '06FEB2019', 'Date', 'Feb 6,2019', 'Date', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA. INC', 'Page 3 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'PRINCIPAL INVESTIGATOR SIGNATURE PAGE', 'Protocol Number:', 'HZNP-TEP-302', 'Version:', '3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Protocol Title:', 'Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating', 'Teprotumumab (HZN-001) Treatment in Subjects with Thyroid Eye', 'Disease (OPTIC-X)', 'Version Date:', '31 January 2019', 'I agree to conduct the study according to the protocol named above. I fully understand that any', 'changes instituted by the Principal Investigator without previous discussion with the Sponsor', 'constitute a violation of the protocol, unless necessary to eliminate an immediate hazard to the', 'safety or well-being of a subject.', 'I acknowledge that I have read and understand the protocol named above and agree to carry out', 'all of its terms in accordance with applicable regulations and laws.', 'I assure that the study drug supplied by the Sponsor will be used only as described in the', 'protocol named above.', 'Signature:', 'Name', 'Date', 'Study Center', 'Address', 'City State Country', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 4 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'SUMMARY OF CHANGES', 'Protocol HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Version 2.0 of the protocol, which was approved 20 April 2018, has been amended to', 'incorporate the change from Protocol Version 2.1 that was specific to Germany:', 'Add the following statement in the exclusion criteria: The exclusion criteria (except those', 'related to screening) of protocol HZNP-TEP-301 also apply to this open-label extension', 'study.', 'Further revisions and clarifications to Version 2.0 of the protocol include:', 'Add diplopia responder rate (defined as the percentage of subjects with baseline diplopia', '0 in study eye who have a reduction of > 1 grade with no corresponding deterioration', '1 grade worsening] in the fellow eye at Week 24) as a secondary endpoint.', 'Add evaluation of pharmacokinetic (PK) parameters of teprotumumab to estimate', 'exposure and understand the PK-PD relationships as an exploratory endpoint.', 'Change the number of teprotumumab doses administered from \"up to 8 infusions based', 'on Investigator judgment\" to \"8 infusions\".', 'Specify the End-of-Treatment (EOT) Visit as Week 24.', 'Add 2 additional follow-up contacts (telephone or email) at 6 and 12 months after the last', 'visit to assess any additional thyroid eye disease (TED) treatment received since last', 'study contact. For subjects who were proptosis non-responders after completion of the', 'Treatment Period in Study HZNP-TEP-301, the last clinic visit was Month 12, with the', 'follow-up contacts at Month 18 and 24. For subjects who relapsed during the Follow-up', 'Period of Study HZNP-TEP-301, the last clinic visit was Week 24, with the follow-up', 'contacts at Month 12 and 18.', 'Clarify that female subjects of childbearing potential who are sexually active with a', 'non-vasectomized male partner must agree to use 2 reliable forms of contraception, one', 'of which is recommended to be hormonal, during the trial and for 180 days after the last', 'dose of study drug.', 'Clarify that male subjects who are sexually active with a female partner of childbearing', 'potential must agree to use a barrier contraceptive method from Baseline through', '180 days after the last dose of study drug.', 'Clarify that Clinical Activity Score (CAS) criteria for determining relapse refers only to', 'the study eye.', 'Amend the CAS relapse criterion to include an increase in CAS of > 2 points since', 'Week 24 with an absolute CAS > 4 following the Week 24 Visit of HZNP-TEP-301.', 'Specify the minimum duration of study drug infusions.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 5 of 118']\n\n###\n\n", "completion": "END"}